DRREDDY1,141.00

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹95,274 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations28,011.132,643.933,700.233,227.9
Other Income894.31,097.31,358.41,422.8
Total Income28,905.433,741.235,058.634,650.7
Expenses
+ Cost of Materials Consumed4,490.15,683.56,501.26,119.2
+ Purchases of Stock-in-Trade4,399.14,841.16,161.66,919.5
+ Changes in Inventories-680.5-544.7-423.6-221.9
+ Employee Benefit Expense5,030.15,580.05,990.96,139.0
+ Finance Costs171.1282.9373.8416.3
+ Depreciation & Amortisation1,470.01,703.72,058.82,119.3
+ Other Expenses6,839.28,536.99,016.69,132.3
Total Expenses21,719.126,083.429,679.330,623.7
EBITDA7,933.18,547.16,453.55,139.8
EBIT6,463.16,843.44,394.73,020.5
Profit
PBT before Exceptional Items7,186.37,657.85,379.34,027.0
Pretax Income7,186.37,657.85,379.34,027.0
+ Current Tax1,945.92,258.11,394.5525.9
+ Deferred Tax-322.8-303.8-159.4331.8
Tax Expense1,623.11,954.31,235.1857.7
+ Share of Associates & JVs14.721.713.414.0
Net Income5,577.95,725.24,157.63,183.3
+ Net Income — Continuing Ops5,563.25,703.54,144.23,169.3
+ Other Comprehensive Income-65.6204.9739.5689.6
Total Comprehensive Income5,512.35,930.14,897.13,872.9
Net Income to Common0.05,655.14,196.03,222.2
Minority Interest0.070.1-38.4-38.9
Per Share
Basic EPS335.2267.8950.4138.69
Diluted EPS334.5967.7950.3538.67
Other Comprehensive Income — detail
+ Other Comprehensive Income204.9739.5689.6
+ Items NOT to be Reclassified to P&L-2.8-29.314.313.1
+ Tax on Items NOT to be Reclassified-2.45.65.4
+ Tax on Items NOT to be Reclassified — alt tag-0.4
+ Items to be Reclassified to P&L-74.9237.6691.6672.7
+ Tax on Items to be Reclassified5.8-39.2-9.2
+ Tax on Items to be Reclassified — alt tag-11.7
Comprehensive Income — Owners of Parent5,512.35,860.04,935.53,911.8
Comprehensive Income — Non-controlling Interests0.070.1-38.4-38.9
Per Share — as-filed variants
Basic EPS — Continuing Operations335.2267.8950.4138.69
Diluted EPS — Continuing Operations334.5967.7950.3538.67
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit19,802.422,664.021,461.020,411.1
Gross Margin %70.6969.4363.6861.43
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)7,186.37,657.85,379.34,027.0
Net Income Adj (tax-effected)5,577.95,725.24,157.63,183.3
EPS Adj335.2267.8950.4138.69
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value0.001.001.001.00
Paid Up Equity Capital83.483.483.583.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.